ONC vs. SVA, TH, MDNA, HBP, MBX, FRX, EDT, HLS, CWEB, and CRDL
Should you be buying Oncolytics Biotech stock or one of its competitors? The main competitors of Oncolytics Biotech include Sernova (SVA), Theratechnologies (TH), Medicenna Therapeutics (MDNA), Helix BioPharma (HBP), Microbix Biosystems (MBX), Fennec Pharmaceuticals (FRX), Spectral Medical (EDT), HLS Therapeutics (HLS), Charlotte's Web (CWEB), and Cardiol Therapeutics (CRDL). These companies are all part of the "medical" sector.
Sernova (TSE:SVA) and Oncolytics Biotech (TSE:ONC) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, community ranking, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and valuation.
In the previous week, Sernova and Sernova both had 1 articles in the media. Oncolytics Biotech's average media sentiment score of 1.05 beat Sernova's score of 0.00 indicating that Sernova is being referred to more favorably in the media.
Sernova's return on equity of -102.66% beat Oncolytics Biotech's return on equity.
Sernova presently has a consensus price target of C$1.50, suggesting a potential upside of 275.00%. Oncolytics Biotech has a consensus price target of C$6.00, suggesting a potential upside of 275.00%.
Sernova has a beta of 1.6, meaning that its stock price is 60% more volatile than the S&P 500. Comparatively, Oncolytics Biotech has a beta of 1.49, meaning that its stock price is 49% more volatile than the S&P 500.
0.1% of Sernova shares are owned by institutional investors. Comparatively, 7.0% of Oncolytics Biotech shares are owned by institutional investors. 14.5% of Sernova shares are owned by company insiders. Comparatively, 6.2% of Oncolytics Biotech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Oncolytics Biotech is trading at a lower price-to-earnings ratio than Sernova, indicating that it is currently the more affordable of the two stocks.
Oncolytics Biotech received 188 more outperform votes than Sernova when rated by MarketBeat users. However, 88.89% of users gave Sernova an outperform vote while only 75.38% of users gave Oncolytics Biotech an outperform vote.
Summary
Oncolytics Biotech beats Sernova on 7 of the 13 factors compared between the two stocks.
Get Oncolytics Biotech News Delivered to You Automatically
Sign up to receive the latest news and ratings for ONC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ONC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Oncolytics Biotech Competitors List
Related Companies and Tools
